In the past week, AMLX stock has gone up by 9.31%, with a monthly gain of 22.94% and a quarterly surge of 50.41%. The volatility ratio for the week is 4.97%, and the volatility levels for the last 30 days are 4.88% for Amylyx Pharmaceuticals Inc. The simple moving average for the past 20 days is 6.60% for AMLX’s stock, with a 34.91% simple moving average for the past 200 days.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
The 36-month beta value for AMLX is also noteworthy at -0.58. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for AMLX is 65.31M, and at present, short sellers hold a 6.33% of that float. The average trading volume of AMLX on June 13, 2025 was 896.56K shares.
AMLX) stock’s latest price update
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)’s stock price has gone rise by 1.85 in comparison to its previous close of 5.42, however, the company has experienced a 9.31% increase in its stock price over the last five trading days. accessnewswire.com reported 2025-06-12 that NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. (“Amylyx” or “the Company”) (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AMLX.
Analysts’ Opinion of AMLX
Mizuho, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $7. The rating they have provided for AMLX stocks is “Outperform” according to the report published on April 07th, 2025.
Robert W. Baird gave a rating of “Outperform” to AMLX, setting the target price at $11 in the report published on November 18th of the previous year.
AMLX Trading at 17.52% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.07% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from FRATES JAMES M, who sale 10,896 shares at the price of $3.47 back on Mar 31 ’25. After this action, FRATES JAMES M now owns 290,988 shares of Amylyx Pharmaceuticals Inc, valued at $37,806 using the latest closing price.
Bedrosian Camille L, the Chief Medical Officer of Amylyx Pharmaceuticals Inc, sale 12,425 shares at $3.47 during a trade that took place back on Mar 31 ’25, which means that Bedrosian Camille L is holding 194,375 shares at $43,082 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- 163.17 for the present operating margin
- 7.76 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at 172.06. The total capital return value is set at -1.03. Equity return is now at value -83.24, with -68.70 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -149.77.
Currently, EBITDA for the company is -301.23 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -340.94. The receivables turnover for the company is -4.24for trailing twelve months and the total asset turnover is -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.05.
Conclusion
In summary, Amylyx Pharmaceuticals Inc (AMLX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
